Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.72 |
| ▸ | HTR1A | P08908 | 6/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.72 |
| ▸ | HTR7 | P34969 | 4/20 | 0.72 |
| ▸ | HTR6 | P50406 | 4/20 | 0.72 |
| ▸ | DRD4 | P21917 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HTR2C | P28335 | 1/20 | 0.72 |
| ▸ | DRD3 | P35462 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791945 | 0.97 | DRD2 (0.70) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL15064476 | 0.92 | SLC6A4 (0.69) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL8554164 | 0.87 | DRD2 (0.69) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL793144 | 0.87 | DRD2 (0.71) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL7136564 | 0.85 | DRD2 (0.67) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL7134140 | 0.84 | DRD2 (0.98) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL1040205 | 0.84 | DRD2 (1.00) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL791317 | 0.83 | DRD2 (0.69) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL793141 | 0.82 | DRD2 (1.00) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL5401393 | 0.81 | DRD2 (0.66) | DRD2HTR1ASLC6A4HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2014-11-13 | — | — | US | disclosed |
| US-8822517-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z O.O. (PL) | 2014-09-02 | — | — | US | disclosed |
| EP-2616440-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | Adamed sp. z o.o. (PL) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035123-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2012-03-22 | — | — | WO | disclosed |
| EP-1121356-B1 | 3-TETRAHYDROPYRIDIN-4-YL INDOLES FOR TREATMENT OF PSYCHOTIC DISORDERS | DUPHAR INT RES (NL) | 2003-01-08 | — | — | EP | disclosed |
| US-6391896-B1 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | DUPHAR INTERNATIONAL RESEARCH BV (NL) | 2002-05-21 | — | — | US | disclosed |
| EP-1200072-A2 | METHOD OF TREATING PSYCHOTIC DISORDERS | Solvay Pharmaceuticals B.V. (NL) | 2002-05-02 | — | — | EP | disclosed |
| EP-1121356-A1 | 3-TETRAHYDROPYRIDIN-4-YL INDOLES FOR TREATMENT OF PSYCHOTIC DISORDERS | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000069424-A2 | METHOD OF TREATING PSYCHOTIC DISORDERS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000023441-A1 | 3-TETRAHYDROPYRIDIN-4-YL INDOLES FOR TREATMENT OF PSYCHOTIC DISORDERS | DUPHAR INTERNATIONAL RESEARCH BV (NL) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | DRD2 3216/4885HTR1A 1354/4885SLC6A4 174/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | DRD2 3216/4885HTR1A 1354/4885SLC6A4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.